| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (NCT05418088) | Sumithira Vasu | 2022-06-30 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors (NCT04851119) | Children's Oncology Group | 2021-11-08 |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation (NCT03602898) | Fred Hutchinson Cancer Center | 2021-06-01 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial (NCT04320888) | National Cancer Institute (NCI) | 2021-05-03 |
| Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma (NCT04640779) | Mayo Clinic | 2021-02-08 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial (NCT04284774) | National Cancer Institute (NCI) | 2020-10-13 |
| CD19-Specific T Cells Post AlloSCT (NCT03579888) | M.D. Anderson Cancer Center | 2020-06-26 |
| Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies (NCT04205409) | University of Washington | 2020-06-05 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (NCT03878524) | OHSU Knight Cancer Institute | 2020-04-01 |
| Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma (NCT04029038) | M.D. Anderson Cancer Center | 2019-05-15 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) (NCT03698994) | National Cancer Institute (NCI) | 2018-11-14 |
| Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT03583424) | Ohio State University Comprehensive Cancer Center | 2018-09-10 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) (NCT03526250) | National Cancer Institute (NCI) | 2018-08-13 |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (NCT03479268) | City of Hope Medical Center | 2018-04-27 |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) (NCT03213652) | National Cancer Institute (NCI) | 2018-04-17 |
| Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer (NCT03432741) | Mayo Clinic | 2018-03-27 |
| Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT03210662) | M.D. Anderson Cancer Center | 2018-02-01 |
| Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer (NCT03333486) | Roswell Park Cancer Institute | 2017-12-07 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) (NCT03213678) | National Cancer Institute (NCI) | 2017-11-28 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) (NCT03213665) | National Cancer Institute (NCI) | 2017-11-13 |
| Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) (NCT03213704) | National Cancer Institute (NCI) | 2017-08-23 |
| Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma (NCT03035331) | Mayo Clinic | 2017-08-15 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (NCT03155620) | National Cancer Institute (NCI) | 2017-07-31 |
| Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02960646) | M.D. Anderson Cancer Center | 2017-01-18 |
| Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (NCT02568553) | National Cancer Institute (NCI) | 2016-11-15 |
| Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant (NCT02861417) | M.D. Anderson Cancer Center | 2016-08-05 |
| Personalized NK Cell Therapy in CBT (NCT02727803) | M.D. Anderson Cancer Center | 2016-05-19 |
| Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant (NCT02662296) | Fred Hutchinson Cancer Center | 2016-03-01 |
| Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis (NCT02593123) | Virginia Commonwealth University | 2015-11-04 |
| Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT02420795) | M.D. Anderson Cancer Center | 2015-11-03 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (NCT02304458) | National Cancer Institute (NCI) | 2015-03-30 |
| Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia (NCT01865617) | Fred Hutchinson Cancer Center | 2013-05-22 |
| Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant (NCT01822509) | National Cancer Institute (NCI) | 2013-05-16 |
| NK Cells in Cord Blood Transplantation (NCT01619761) | M.D. Anderson Cancer Center | 2013-05-03 |
| Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma (NCT01703949) | University of Washington | 2013-03-20 |
| Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies (NCT01527045) | Fred Hutchinson Cancer Center | 2012-09-25 |
| Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (NCT01567709) | National Cancer Institute (NCI) | 2012-04-16 |
| Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma (NCT01318317) | City of Hope Medical Center | 2011-09-19 |
| Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma (NCT01381692) | National Cancer Institute (NCI) | 2011-07-20 |
| Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers (NCT01254578) | National Cancer Institute (NCI) | 2010-11-24 |
| Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma (NCT01035463) | University of Nebraska | 2009-11-12 |
| Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma (NCT00703664) | National Cancer Institute (NCI) | 2008-07-09 |
| Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma (NCT00082888) | National Cancer Institute (NCI) | 2004-03-24 |
| Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant (NCT00068718) | Fred Hutchinson Cancer Center | 2003-05-01 |
| Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma (NCT00005803) | Fred Hutchinson Cancer Center | 1999-09-01 |